Immunicum, a Swedish biopharmaceutical company developing therapeutic cancer immunotherapies, has submitted an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) in the US. The application is requesting approval to treat kidney cancer patients with the cancer immune primer, INTUVAX®, in its ongoing MERECA (MEtastatic REnal cell CArcinoma) phase II trial.
INTUVAX® is a unique cancer immune primer currently being tested in clinical trials for the treatment of kidney cancer and liver cancer as well as GIST (gastrointestinal stromal tumour). Results from Immunicum’s completed phase I/II trial for treatment of kidney cancer have been promising. Approval from the FDA is expected within 30 days.